Achilles Therapeutics (NASDAQ: ACHL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.500 | -0.450 | 0.0500 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Achilles Therapeutics (NASDAQ: ACHL) through any online brokerage.
Other companies in Achilles Therapeutics’s space includes: Adverum Biotechnologies (NASDAQ:ADVM), OncoCyte (NASDAQ:OCX), Ambrx Biopharma (NYSE:AMAM), TCR2 Therapeutics (NASDAQ:TCRR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by JP Morgan on Monday, April 26, 2021. The analyst firm set a price target for 11.00 expecting ACHL to rise to within 12 months (a possible 340.00% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Achilles Therapeutics (NASDAQ: ACHL) is $2.5 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Achilles Therapeutics.
Achilles Therapeutics’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Achilles Therapeutics.
Achilles Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.